Castle Biosciences(US:CSTL) Globenewswire·2026-01-11 21:00Core Insights - Castle Biosciences, Inc. expects total revenue for 2025 to exceed $340 million, surpassing the previously guided range of $327-335 million [1] - The company reported a 37% increase in total test reports for core revenue drivers (DecisionDx-Melanoma, TissueCypher) in 2025 compared to 2024 [5] - Year-end 2025 cash, cash equivalents, and marketable investment securities are projected to be approximately $300 million [1] Financial Performance - Preliminary results for the fourth quarter of 2025 indicate a 42% increase in total test reports for core revenue drivers compared to Q4 2024 [4] - DecisionDx-Melanoma test reports delivered in Q4 2025 were 10,022, up from 8,672 in Q4 2024 [4] - TissueCypher Barrett's Esophagus test reports delivered in Q4 2025 were 11,803, compared to 6,672 in Q4 2024 [4] Product Launch and Market Expansion - The company launched AdvanceAD-Tx on a limited access basis in November 2025, with over 50% of the 150 clinician offices that were granted access ordering the test within the first five weeks [4] - The launch of AdvanceAD-Tx is expected to materially expand Castle's total addressable market [3] Test Report Trends - In 2025, DecisionDx-Melanoma test reports totaled 39,083, an increase from 36,008 in 2024 [5] - TissueCypher Barrett's Esophagus test reports in 2025 were 39,014, significantly up from 20,956 in 2024 [6] - DecisionDx-SCC test reports delivered in 2025 were 17,294, compared to 16,348 in 2024 [12] Cash Position - As of year-end 2025, the company expects to have approximately $116 million in cash and cash equivalents, along with about $184 million in marketable investment securities [7]